The cgc stock price performance has been lagging the broader cannabis index this quarter. However, relative strength improvement in the last two weeks hints at potential re-rating by institutional players. Wednesday’s price action suggests investors are securing profits from the speculative rally, acknowledging that the road to any concrete legislative change remains complex and uncertain. Prior to today's trading, shares of the company had lost 10.84% lagged the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67%. Key technical pivot lies at $2.40; a breakdown below may invite further downside toward $2.35 as market liquidity thins.